Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MPLT
stocks logo

MPLT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is 31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is 31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.700
sliders
Low
28.00
Averages
31.00
High
34.00
Current: 20.700
sliders
Low
28.00
Averages
31.00
High
34.00
Stifel
Paul Matteis
Buy
maintain
$28
2025-12-03
Reason
Stifel
Paul Matteis
Price Target
$28
2025-12-03
maintain
Buy
Reason
After Bristol Myers (BMY) announced this morning that the ADEPT-2 study of Cobenfy in in Alzheimer's disease psychosis will continue enrolling additional patients after a review identified irregularities due to trial conduct at some sites, Stifel analyst Paul Matteis contends that the study continuation has "grey implications, but at face is a win" for MapLight Therapeutics (MPLT) and overall this is a positive, though there are some lingering questions. For MapLight, the firm thinks there's a chance that their muscarinic drug has a wider therapeutic index in elderly subjects and the firm sees "an upside risk/reward" as the current valuation "arguably prices in very little ADP credit." Stifel has a Buy rating and $28 price target on MapLight shares, which are up $3.61, or 28%, to $16.50 in morning trading.
Leerink
Marc Goodman
Outperform
initiated
$30
2025-11-21
Reason
Leerink
Marc Goodman
Price Target
$30
2025-11-21
initiated
Outperform
Reason
Leerink analyst Marc Goodman initiated coverage of MapLight Therapeutics with an Outperform rating and $30 price target. The firm is bullish on the muscarinic space and says MapLight's lead asset ML-007C-MA has a potentially better clinical profile than Cobenfy. ML-007C-MA is in Phase 2 development for the treatment of Alzheimer's disease psychosis, which is a large market with significant unmet need, the analyst tells investors in a research note.
Morgan Stanley
initiated
$34
2025-11-21
Reason
Morgan Stanley
Price Target
$34
2025-11-21
initiated
Reason
Morgan Stanley initiated coverage of MapLight Therapeutics with an Overweight rating and $34 price target. The company's lead asset, ML007-C-MA, has "best in class potential" in the greater than $20B market for antipsychotics, the analyst tells investors in a research note. The firm says approved antipsychotics are all very similar, with high switch rates, positioning novel drug mechanisms to gain market share.
Stifel
Buy
initiated
$28
2025-11-21
Reason
Stifel
Price Target
$28
2025-11-21
initiated
Buy
Reason
Stifel initiated coverage of MapLight Therapeutics with a Buy rating and $28 price target. The firm sees the company as a potential second-mover in the muscarinic space. Despite the slower than expected launch of Cobenfy, the muscarinic space represents a very large revenue opportunity, the analyst tells investors in a research note. Stifel believes MapLight's ML-007C-MA offers potential avenues for differentiation, specifically around more convenient dosing and improved tolerability.
Jefferies
Andrew Tsai
Buy
initiated
$32
2025-11-21
Reason
Jefferies
Andrew Tsai
Price Target
$32
2025-11-21
initiated
Buy
Reason
Jefferies analyst Andrew Tsai initiated coverage of MapLight Therapeutics with a Buy rating and $32 price target. The company's ML-007C-MA has a 30%-40% probability of success to generate superior Phase II schizophrenia data, driving a potential 100% stock move and enabling the Street to assign more value to its second program in Alzheimer's psychosis, the analyst tells investors in a research note. Jefferies believes MapLight has an "intriguing" Phase II pipeline that could disrupt the central nervous system landscape.
See All Ratings

Valuation Metrics

The current forward P/E ratio for MapLight Therapeutics Inc (MPLT.O) is -5.50, compared to its 5-year average forward P/E of -4.23. For a more detailed relative valuation and DCF analysis to assess MapLight Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.23
Current PE
-5.50
Overvalued PE
-3.63
Undervalued PE
-4.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.36
Undervalued EV/EBITDA
-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MPLT News & Events

Events Timeline

(ET)
2025-10-27
12:00:19
MapLight Therapeutics Debuts at $19 After IPO Set at $17 per Share
select
2025-10-27
10:31:25
MapLight Therapeutics Set to Debut at $27.30 After IPO Pricing of $17
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
MapLight Therapeutics Raises $296.5 Million in IPO, Funding Secured Through 2027
  • Successful Financing: MapLight Therapeutics completed a $296.5 million IPO and concurrent private placement in October 2025, selling 17,439,207 shares and netting $269.8 million, which provides substantial funding for ongoing research and development efforts.
  • Clinical Trial Progress: The ongoing ZEPHYR and VISTA trials are expected to report topline results in the second half of 2026 and 2027, respectively, with ZEPHYR enrolling 300 schizophrenia patients and VISTA targeting psychosis symptoms in Alzheimer's disease, showcasing the company's potential in CNS disease research.
  • Strong Financial Position: As of September 30, 2025, the company reported $227.2 million in cash and short-term investments, which is projected to fund operations through 2027, indicating effective financial management and operational sustainability.
  • Increased R&D Spending: Research and development expenses for Q3 2025 reached $27.1 million, up from $16.8 million in Q3 2024, reflecting significant investments in clinical trials and employee-related costs, underscoring the company's commitment to new drug development.
[object Object]
Preview
9.5
12-04NASDAQ.COM
MapLight to Announce Schizophrenia Trial Findings in Second Half of 2026

  • Financial Results: MapLight Therapeutics reported a net loss of $29.4 million in Q3 2025, an increase from $19.0 million in the same quarter last year, with R&D expenses rising to $27.1 million due to higher clinical trial costs.

  • Pipeline Progress: The company is advancing several drug candidates, including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, with Phase 2 trial results expected in 2026 and 2027, respectively.

  • Upcoming Studies: ML-004 for autism spectrum disorder has completed enrollment in its Phase 2 study, with results anticipated in late 2026, while ML-021 for Parkinson's disease is set for IND-enabling studies completion in the same timeframe.

  • Stock Performance: Following the financial report, MPLT shares surged 31% to close at $16.92, with the stock trading between $12.24 and $20.86 over the past year.

[object Object]
Preview
9.5
12-03Benzinga
Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining approximately 100 points on Wednesday.

  • Marvell Technology Earnings Report: Marvell Technology, Inc. reported better-than-expected third-quarter earnings, with adjusted earnings of 76 cents per share and revenue of $2.08 billion, leading to a 7.5% increase in its stock price.

  • Notable Stock Gains: Several companies saw significant stock price increases, including Ambitions Enterprise Management Co. (up 32%), MapLight Therapeutics, Inc. (up 23%), and Aeva Technologies, Inc. (up 19.9%).

  • Other Companies' Performance: American Eagle Outfitters, Inc. and Microchip Technology Incorporated also reported strong earnings, contributing to their respective stock price increases of 13.3% and 9.5%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MapLight Therapeutics Inc (MPLT) stock price today?

The current price of MPLT is 20.7 USD — it has increased 3.01 % in the last trading day.

arrow icon

What is MapLight Therapeutics Inc (MPLT)'s business?

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

arrow icon

What is the price predicton of MPLT Stock?

Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is 31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MapLight Therapeutics Inc (MPLT)'s revenue for the last quarter?

MapLight Therapeutics Inc revenue for the last quarter amounts to -19.99M USD, decreased % YoY.

arrow icon

What is MapLight Therapeutics Inc (MPLT)'s earnings per share (EPS) for the last quarter?

MapLight Therapeutics Inc. EPS for the last quarter amounts to -17820000.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for MapLight Therapeutics Inc (MPLT)'s fundamentals?

The market is revising No Change the revenue expectations for MapLight Therapeutics, Inc. (MPLT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 21.76%.
arrow icon

How many employees does MapLight Therapeutics Inc (MPLT). have?

MapLight Therapeutics Inc (MPLT) has 0 emplpoyees as of December 13 2025.

arrow icon

What is MapLight Therapeutics Inc (MPLT) market cap?

Today MPLT has the market capitalization of 930.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free